Online citations, reference lists, and bibliographies.
← Back to Search

Mixed Amphetamine Salts Extended-Release In The Treatment Of Adult ADHD: A Randomized, Controlled Trial

R. Weisler, J. Biederman, T. Spencer, T. Wilens, S. Faraone, A. Chrisman, S. C. Read, S. Tulloch
Published 2006 · Medicine, Psychology

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
ABSTRACT Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a serious neurobehavioral disorder of childhood onset that often persists into adolescence and adulthood. Functional impairments, underachievement, and difficult interpersonal relationships illustrate the need for effective treatment of ADHD through adulthood. Method: This prospective, multisite, randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study was conducted to assess the efficacy, safety, and duration of action of mixed amphetamine salts extended-release (MAS XR) in adults with ADHD, combined type. Adults ≥ 18 years of age were given placebo or MAS XR 20, 40, or 60 mg/day for 4 weeks. The main outcome measures were the ADHD Rating Scale and Conners' Adult ADHD Rating Scale Short Version Self-Report (CAARS-S-S). Results: Two hundred fifty-five subjects were randomly assigned to treatment with MAS XR or placebo. MAS XR treatment was associated with statistically and clinically significant ADHD symptom reduction at endpoint; mean ADHD Rating Scale scores were 18.5 for the 20-mg group (P=.001), 18.4 for the 40-mg group (P<.001), and 18.5 for the 60-mg group (P<.001). Adults with severe symptoms (ADHD Rating Scale score ≥32 at baseline) had significantly greater symptom reduction with the highest MAS XR dose (60 mg/day), however, this dose-response relationship was determined by post-hoc analysis. The mean MAS XR effect size was 0.8. Statistically significant (P<.05) improvements in CAARS-S-S ADHD index scores occurred at 4- and 12-hours postdose for all MAS XR groups, indicating a 12-hour duration of effect. Symptoms improved within the first treatment week. Most adverse events reported were mild or moderate in intensity, arid the most commonly reported adverse events were consistent with the known profile of stimulant medications. Vital signs and electrocardiograms showed no clinically significant cardiovascular changes. Conclusion: These results suggest that MAS XR is safe and effective in adults with ADHD and controlled ADHD symptoms for up to 12 hours.
This paper references
D-amphetamine-induced release of "newly synthesized" and "stored" dopamine from the caudate nucleus in vivo.
C. Chiueh (1975)
10.1001/ARCHPSYC.1979.01780060065007
Hyperactives as young adults: a controlled prospective ten-year follow-up of 75 children.
G. Weiss (1979)
Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.
J. F. Fischer (1979)
10.1016/0893-133X(89)90029-8
Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children.
B. Borcherding (1989)
10.1097/00004583-199107000-00040
Attention Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment
L. Silver (1991)
Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey.
R. Barkley (1993)
10.1001/ARCHPSYC.1993.01820190067007
Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.
S. Mannuzza (1993)
10.1001/ARCHPSYC.1995.03950180020004
A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.
T. Spencer (1995)
A doubleblind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder
T Spencer (1995)
10.1177/108705479700200302
Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD
R. Millstein (1997)
10.1016/S0166-4328(97)00175-7
Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration
M. Solanto (1998)
Developmental course, adult outcome, and clinic-referred ADHD adults
RA Barkley (1998)
10.1097/00004583-199908000-00022
AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs.
H. Gutgesell (1999)
10.1176/APPI.AJP.157.5.816
Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.
J. Biederman (2000)
10.1176/APPI.PS.51.2.169
Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults.
R. Castaneda (2000)
10.1542/peds.105.5.1158
Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder
Subcommittee on Attention-Deficit (2000)
10.1002/1098-2779(2000)6:3<214::AID-MRDD9>3.0.CO;2-M
Attention-deficit/hyperactivity disorder: perspectives from neuroimaging.
T. Hale (2000)
10.1016/S0006-3223(00)00889-1
Attention-deficit/hyperactivity disorder in adults: an overview
S. Faraone (2000)
Attention-deficit/hyperactivity in adults: an overview
SV Faraone (2000)
Failed attempts at intranasal abuse of Concerts [letter
SL Jaffe (2000)
DP-1: Profile of General Demographic Characteristics: 2000. Data set: Census
(2000)
Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom type
J Biederman (2000)
10.1176/APPI.AJP.158.2.282
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
T. Wilens (2001)
10.1001/ARCHPSYC.58.8.775
Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.
T. Spencer (2001)
10.1592/phco.22.16.1405.33687
SLI381 (Adderall XR), a Two‐Component, Extended‐Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled Administration
S. Tulloch (2002)
10.1017/S1092852900017818
A Review of Adult ADHD: A Neuropsychological and Neuroimaging Perspective
R. Kaplan (2002)
10.1097/00004583-200207000-00002
Attempted abuse of concerta.
P. Ciccone (2002)
10.1097/00004583-200201000-00003
Failed attempts at intranasal abuse of Concerta.
S. Jaffe (2002)
10.1542/PEDS.110.2.258
A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder.
J. Biederman (2002)
10.2105/AJPH.92.2.231
Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina.
A. Rowland (2002)
10.1016/S0006-3223(02)01671-2
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
D. Michelson (2003)
The worldwide prevalence of ADHD: is it an American condition?
S. Faraone (2003)
10.2165/00023210-200317020-00004
Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder
J. Swanson (2003)
10.1097/01.CHI.0000046863.56865.FE
Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.
J. McCracken (2003)
10.1001/JAMA.289.19.2560
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
A. Chobanian (2003)
10.1161/01.HYP.0000107251.49515.C2
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
A. Chobanian (2003)
10.1097/01.jcp.0000108984.11879.95
Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder
S. Faraone (2004)
10.1001/ARCHINTE.164.11.1221
Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care.
S. Faraone (2004)
Meta - analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disor
SV Faraone (2004)
10.1016/j.biopsych.2005.01.027
Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study
T. Wilens (2005)
10.1017/S109285290000239X
Single- and Multiple-Dose Pharmacokinetics of an Oral Mixed Amphetamine Salts Extended-Release Formulation in Adults
S. Clausen (2005)
10.1176/APPI.AJP.163.4.716
The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.
R. Kessler (2006)
10.4088/JCP.V67N0403
Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community.
J. Biederman (2006)
10.1097/01.CHI.0000199027.68828.B3
Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications.
T. Wilens (2006)
A randomized , double - blind , plocebtKontrolled , laboratory classroom assessment of methylphenidote tronsdermal system in children with ADHD . 1 Atten Disoid
JJ McGough (2006)
10.1007/978-1-59745-313-4_1
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
B. Epstein (2007)



This paper is referenced by
10.1007/978-3-319-56015-1_319-1
Efficacy of Amphetamines, Methylphenidate, and Modafinil in the Treatment of Mental Disorders
W. Retz (2021)
10.1089/cap.2020.0012
Post hoc Responder and Remission Analyses from Two Studies of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults with Attention-Deficit/Hyperactivity Disorder
L. Adler (2020)
10.1371/journal.pone.0240584
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis
Jesse Elliott (2020)
10.31436/imjm.v17i2.255
Pharmacotherapy for Comorbid Adult Attention-Deficit Hyperactivity Disorder and Stimulant Dependence: A Systematic Review
Woon LS (2020)
10.1177/1087054720961819
Improved Executive Function in Adults Diagnosed With Attention-Deficit/ Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled Studies.
T. Brown (2020)
10.1080/00325481.2019.1574402
A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD
S. Wigal (2019)
10.1177/1060028018795703
Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis
M. Stuhec (2019)
10.1177/1087054719879502
The Impact of ADHD Treatment on Intimate Partner Violence in a Forensic Psychiatry Setting
Nannet J L Buitelaar (2019)
10.1007/s40268-019-0267-y
Effects of Food on the Bioavailability of Amphetamine in Healthy Adults After Administration of SHP465 Mixed Amphetamine Salts Extended-Release Capsules
Y. Wang (2019)
10.1080/14656566.2019.1618270
Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD)
G. Perugi (2019)
10.1007/S40267-018-0539-6
Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use
K. Lyseng-Williamson (2018)
10.1080/00325481.2018.1389227
Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment
T. Wigal (2018)
10.1007/s40263-018-0503-y
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
T. Wigal (2018)
10.1080/00325481.2018.1481712
A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design
T. Wigal (2018)
10.1007/s40263-017-0455-7
Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study
R. Weisler (2017)
10.1371/journal.pone.0180131
Many-to-one comparisons after safety selection in multi-arm clinical trials
G. Hlavin (2017)
10.1177/1087054712474685
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years
F. López (2017)
10.1016/j.euroneuro.2017.05.005
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial
R. Cooper (2017)
10.1155/2017/1364894
Adult ADHD: Questioning Diagnosis and Treatment in a Patient with Multiple Psychiatric Comorbidities
Robert Karoly Chu (2017)
10.1177/2042098616679636
Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes
J. Martinez-Raga (2017)
10.1177/1087054717696771
Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial
G. Frick (2017)
10.1177/1087054713518242
Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study
R. Weisler (2017)
10.1089/cap.2016.0129
Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
D. Babinski (2017)
10.1080/14740338.2017.1317344
The safety of extended-release drug formulations for the treatment of ADHD
A. Childress (2017)
10.1080/14999013.2016.1160962
Screening for ADHD Among Offenders of Intimate Partner Violence
Nannet J L Buitelaar (2016)
10.1586/14737175.2016.1135735
Alternative pharmacological strategies for adult ADHD treatment: a systematic review
M. Buoli (2016)
10.1176/APPI.FOCUS.20150022
Attention-Deficit Hyperactivity Disorder Across the Lifespan.
S. Pliszka (2016)
10.1007/978-1-4899-7627-7_31
Return to Work in Mild Cognitive Disorders
M. Ettenhofer (2016)
10.15344/2455-2356/2015/103
Psychosis Requiring Hospitalization in an Adult ADHD Patient on a Therapeutic Stimulant: A Case Report and Review of Treatment Alternatives
M. Gable (2015)
10.23860/diss-marraccini-marisa-2015
A META-ANALYSIS OF PRESCRIPTION STIMULANT EFFICACY: ARE STIMULANTS NEUROCOGNITIVE ENHANCERS?
M. Marraccini (2015)
10.1055/b-0034-78426
Clinical Case Studies
M. Gable (2015)
10.1001/jamapsychiatry.2015.41
Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
F. Levin (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar